Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin

Cancer Control

Volumn 14, Issue 2, 2007, Pages 112-123

  Rezania, Dorna ^a   Sokol, Lubomir ^a   Cualing, Hernani D ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ALEMTUZUMAB; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTHRACYCLINE DERIVATIVE; BASILIXIMAB; BEXAROTENE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DENILEUKIN DIFTITOX; DEPSIPEPTIDE; DOXORUBICIN; FR 901228; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMMUCILLIN H; IMMUNOTOXIN LMB2; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; NELARABINE; PREDNISONE; PSORALEN; RETINOID; SIPLIZUMAB; VINCRISTINE; VORINOSTAT; ZANOLIMUMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; CUTANEOUS ADULT T CELL LEUKEMIA; CUTANEOUS ADULT T CELL LYMPHOMA; CUTANEOUS GAMMA DELTA T CELL LYMPHOMA; CUTANEOUS T CELL LYMPHOMA; DIFFERENTIAL DIAGNOSIS; DRUG MECHANISM; ERYTHEMA NODOSUM; EXTERNAL BEAM RADIOTHERAPY; EXTRANODAL NATURAL KILLER T CELL LYMPHOMA; HISTOPATHOLOGY; HUMAN; LUPUS ERYTHEMATOSUS; LYMPHOBLASTOMA; LYMPHOMA; MONOTHERAPY; MORTALITY; MYCOSIS FUNGOIDES; NATURAL KILLER CELL; PANNICULITIS; PERIPHERAL NATURAL KILLER CELL LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PRIMARY CUTANEOUS AGGRESSIVE EPIDERMOTROPIC CD+8 T CELL LYMPHOMA; PRIMARY CUTANEOUS CD+4SMALL TO MEDIUM SIZED PLEOMORPHIC T CELL LYMPHOMA; PUVA; REVIEW; SKIN TUBERCULOSIS; SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA; T CELL LEUKEMIA; T CELL LYMPHOMA; UNSPECIFIED PRIMARY CUTANEOUS PERIPHERAL T CELL LYMPHOMA;

EID: 34047149879     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480701400204     Document Type: Review

References (65)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909-3918.
2. Groves FD, Linet MS, Travis LB, et al. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histological subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240-1251.
3. Dores GM, Anderson WF, Devesa SS. Cutaneous lymphomas reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results Program: applying the new WHO-European Organisation for Research and Treatment of Cancer classification system. J Clin Oncol. 2005;23:3390-3395.
4. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-3785. Epub 2005 Feb 3.
5. Burg G, Kempf W, Cozzio A, et al. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol. 2005;32:647-674.
6. Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T-cell lymphoma. J Clin Invest. 2005;115:798-812.
7. Hudak S, Hagen M, Liu Y, et al. Immune surveillance and effector functions of CCR10 (+) skin homing T cells. J Immunol. 2002;169:1189-1196.
8. Kabelitz D, Marischen L, Oberg HH, et al. Epithelial defence by gamma delta T cells. Int Arch Allergy Immunol. 2005;137:73-81. Epub 2005 Apr 12.
9. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274.
10. Alibert JLM. Description des Maladies de la Peau Observees a l'Hopital St. Louis. Barrois L'aine et Fils. 1806:413-446.
11. Willemze R, Meijer CJ. Classification of cutaneous T-cell lymphoma: from Alibert to WHO-EORTC. J Cutan Pathol. 2006;33(suppl 1):18-26.
12. Edelson RL. Cutaneous T-cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol. 1980;2:89-106.
13. Lennert K. Non-Hodgkin's lymphomas: principles and application of the Kiel classification [in German]. Verh Dtsch Ges Pathol. 1992;76:1-13.
14. Rilke F, Giardini R. Working formulation of malignant lymphomas for clinical use [in Italian]. Pathologica. 1982;74:151-160.
15. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
16. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354-371.
17. Jaffe ES HN, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
18. Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003;101:3407-3412. Epub 2003 Jan 9.
19. Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/natural killer cell cutaneous lymphomas: report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer. 2003;97:610-627.
20. Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood. 2003;102:2213-2219. Epub 2003 May 15.
21. Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol. 2005;16:206-214.
22. Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T-cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol. 1999;155:483-492.
23. Massone C, Chott A, Metze D, et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol. 2004;28:719-735.
24. Lozzi GP, Massone C, Citarella L, et al. Rimming of adipocytes by neoplastic lymphocytes: a histopathologic feature not restricted to subcutaneous T-cell lymphoma. Am J Dermatopathol. 2006;28:9-12.
25. Marzano AV, Berti E, Paulli M, et al. Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases. Arch Dermatol. 2000;136:889-896.
26. Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitislike T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol. 1998;22:881-893.
27. Ghobrial IM, Weenig RH, Pittlekow MR, et al. Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma. 2005;46:703-708.
28. Go RS, Wester SM. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer. 2004;101:1404-1413.
29. Craig AJ, Cualing H, Thomas G, et al. Cytophagic histiocytic panniculitis - a syndrome associated with benign and malignant panniculitis: case comparison and review of the literature. J Am Acad Dermatol. 1998;39(5 Pt 1):721-736.
30. Massone C, Lozzi GP, Egberts F, et al. The protean spectrum of non-Hodgkin lymphomas with prominent involvement of subcutaneous fat. J Cutan Pathol. 2006;33:418-425.
31. Slater DN. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol. 2005;153:874-880.
32. Kadin ME. Cutaneous gamma delta T-cell lymphomas: how and why should they be recognized? Arch Dermatol. 2000;136:1052-1054.
33. Toro JR, Beaty M, Sorbara L, et al. Gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch Dermatol. 2000;136:1024-1032.
34. Zucca E, Zinzani PL. Understanding the group of peripheral T-cell lymphomas, unspecified. Curr Hematol Rep. 2005;4:23-30.
35. Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15:1467-1475.
36. Fink-Puches R, Zenahlik P, Back B, et al. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood. 2002;99:800-805.
37. Rizvi MA, Evens AM, Tallman MS, et al. T-cell non-Hodgkin lymphoma. Blood. 2006;107:1255-1264. Epub 2005 Oct 6.
38. Setoyama M, Katahira Y, Kanzaki T. Clinicopathologic analysis of 124 cases of adult T-cell leukemia/lymphoma with cutaneous manifestations: the smouldering type with skin manifestations has a poorer prognosis than previously thought. J Dermatol. 1999;26:785-790.
39. Huber MA, Staib G, Pehamberger H, et al. Management of refractory early-stage cutaneous T-cell lymphoma. Am J Clin Dermatol. 2006;7:155-169.
40. Marzano AV, Ghislanzoni M, Gianelli U, et al. Fatal CD8+ epidermotropic cytotoxic primary cutaneous T-cell lymphoma with multiorgan involvement. Dermatology. 2005;211:281-285.
41. von den Driesch P, Coors EA. Localized cutaneous small to mediumsized pleomorphic T-cell lymphoma: a report of 3 cases stable for years. J Am Acad Dermatol. 2002;46:531-535.
42. Mraz-Gernhard S, Natkunam Y, Hoppe RT, et al. Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol. 2001;19:2179-2188.
43. Friedmann D, Wechsler J, Delfau MH, et al. Primary cutaneous pleomorphic small T-cell lymphoma. A review of 11 cases. The French Study Group on Cutaneous Lymphomas. Arch Dermatol. 1995;131:1009-1015.
44. Gniadecki R, Rossen K, Ralfkier E, et al. CD56+ lymphoma with skin involvement: clinicopathologic features and classification. Arch Dermatol. 2004;140:427-436.
45. Pol-Rodriguez MM, Fox LP, Sulis ML, et al. Extranodal nasal-type natural killer T-cell lymphoma in an adolescent from Bangladesh. J Am Acad Dermatol. 2006;54(5 suppl):S192-S197.
46. Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997;89:4501-4513.
47. Cheung MM, Chan JK, Wong KF. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol. 2003;40:221-232.
48. Bekkenk MW, Jansen PM, Meijer CJ, et al. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. 2004;15:1097-1108.
49. Dummer R, Potoczna N, Haffner AC, et al. A primary cutaneous non-T, non-B CD4+, CD56+ lymphoma. Arch Dermatol. 1996;132:550-553.
50. Pagano L, Gallamini A, Trape G, et al. NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey. Ann Oncol. 2006;17:794-800. Epub 2006 Feb 23.
51. Siu LL, Wong KF, Chan JK, et al. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol. 1999;155:1419-1425.
52. Hoshida Y, Hongyo T, Jia X, et al. Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T-cell lymphoma in northeast district of China. Cancer Sci. 2003;94:297-301.
53. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103:216-221. Epub 2003 Aug 21.
54. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428-437.
55. Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998;16:70-77.
56. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474-2479. Epub 2003 Nov 26.
57. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood. 1998;92:76-82.
58. Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol. 1990;1:45-50.
59. Peipp M, Kupers H, Saul D, et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res. 2002;62:2848-2855.
60. Stadler R, Kremer A. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids. Semin Oncol. 2006;33(1 suppl 3):S7-S10.
61. Foss F. Immunomodulatory effects of rexinoids. Semin Oncol. 2006;33(1 suppl 3):S21-S25.
62. Dummer R. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL). Semin Oncol. 2006;33(1 suppl 3):S33-S36.
63. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic SAMA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31-39. Epub 2006 Sep 7.
64. Galmarini CM. Drug evaluation: forodesine-PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor. Drugs. 2006;9:712-722
65. Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005;23:3376-3382.